These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24582569)

  • 1. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
    Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients.
    Yilmaz B; Can G; Ucmak F; Arslan AO; Solmaz I; Unlu O; Düzenli S; Korkmaz U; Kurt M; Senates E
    Acta Gastroenterol Belg; 2016; 79(2):206-10. PubMed ID: 27382939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
    Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.
    Visco-Comandini U; Lapa D; Taibi C; Angeletti C; Capobianchi MR; Garbuglia AR
    Dig Liver Dis; 2014 Apr; 46(4):348-52. PubMed ID: 24387833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
    Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
    Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
    J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta.
    Ispiroglu M; Bahcecioglu IH; Demirel U; Yalniz M
    J Infect Dev Ctries; 2017 Jan; 11(1):58-64. PubMed ID: 28141591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis D.
    Abbas Z; Yakoob J; Umer MA; Abbas M; Hamid S
    Antivir Ther; 2015; 20(5):529-33. PubMed ID: 25668821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent.
    Ranjan P; Fletcher GJ; Radhakrishnan M; Sivakumar J; Premkumar PS; Goel A; Zachariah UG; Abraham P
    Indian J Med Microbiol; 2016; 34(3):335-41. PubMed ID: 27514956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
    J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
    J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
    Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.